Target intelligence / Profile preview

FAM222A antisense RNA 1 (FAM222A-AS1)

Target: FAM222A-AS1
Molecular classification: Long non-coding RNA (lncRNA), Other (non-protein coding RNA)

Overview

FAM222A antisense RNA 1 (FAM222A-AS1) is a cytoplasm-localized long non-coding RNA found to be overexpressed in various cancers, especially colorectal cancer and lung adenocarcinoma. FAM222A-AS1 acts predominantly as a competitive endogenous RNA (ceRNA), sponging miR-let-7f to upregulate MYH9, and thereby promotes proliferation, migration, and invasion of tumor cells. Its expression is regulated under stress conditions and may also play a role in the rapid cellular response to chemical exposures in neural stem cells. High levels of FAM222A-AS1 correlate with poor prognosis in cancer patients, making it a candidate for biomarker development and therapeutic targeting in oncology.

Other names: FAM222A antisense RNA 1FAM222A-AS1FAM222A antisense RNA 1 (non-protein coding)

Mechanism of action

RNA interference or antisense oligonucleotide approaches could theoretically silence FAM222A-AS1 expression, which suppresses its tumor-promoting effects. Modulation of the miR-let-7f/MYH9 axis via ceRNA competition

Biological functions

Regulation of cell proliferationRegulation of cell migration and invasionmiRNA sponge: sequesters miR-let-7f, affecting post-transcriptional gene regulationAcute stress response: regulated by oxidative stress, heavy metals, protein synthesis stress

Disease associations

Cancer (colorectal cancer, lung adenocarcinoma)Possible roles in neurobiology and stress response

Safety considerations

No specific safety concerns are reported, but as with most lncRNA targets, broad interference might lead to off-target effects due to context-dependent expression in multiple tissues

Biomarkers

Elevated FAM222A-AS1 expression is a prognostic biomarker for poor overall survival and relapse in colorectal cancer and lung adenocarcinoma

Beyond the preview

Go deeper on FAM222A antisense RNA 1 (FAM222A-AS1).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Explore the programs pursuing this target and their development progress.

Drug candidates
Developers
Development stage

Clinical trials

Follow the clinical studies evaluating therapies directed at this target.

Trial design
Status
Readouts

Competitive landscape

Compare approaches across drug candidates, modalities, and indications.

Programs
Modalities
Indications

Literature & evidence

Investigate the research and source evidence behind target biology and development.

Publications
Sources
Analysis

Patents

Explore patent activity around therapies and technologies addressing this target.

Patents
Assignees
Technologies

Research & analysis

Connect target biology, drug development, and emerging evidence in your research.

Biology
Development news
Analysis

Bring the full picture into focus.

See how Gosset can support your research on FAM222A antisense RNA 1 (FAM222A-AS1).

Explore the full profile